Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial

BackgroundAntineutrophil cytoplasmic antibody (ANCA)–associated vasculitis is a serious, often life-threatening disease. In new-onset disease or a relapse, the standard treatment is immunosuppressive therapy with glucocorticoids; these therapies are associated with substantia...

Full description

Bibliographic Details
Main Authors: Merkel, Peter A, Jayne, David R, Wang, Chao, Hillson, Jan, Bekker, Pirow
Format: Article
Language:English
Published: JMIR Publications 2020-04-01
Series:JMIR Research Protocols
Online Access:https://www.researchprotocols.org/2020/4/e16664